Novocure Launches 31% After Pancreatic Cancer Treatment Succeeds

Novocure Launches 31% After Pancreatic Cancer Treatment Succeeds·Investor's Business Daily

Novocure stock catapulted early Monday after the company's cancer-treating device succeeded in a study of patients with pancreatic cancer.

Advertisement